Management of patients susceptible to malignant hyperthermia: A surgeon's perspective

Int J Pediatr Otorhinolaryngol. 2022 Aug:159:111187. doi: 10.1016/j.ijporl.2022.111187. Epub 2022 May 30.

Abstract

Objectives: Malignant hyperthermia (MH) susceptibility caries broad implications for the care of pediatric surgical patients. While precautions must often be taken for only a vague family history, two options exist to assess MH-susceptibility. We evaluate the use of MH precautions and susceptibility testing at a freestanding children's hospital.

Methods: This single institution retrospective cohort study identified patients of any age who received general anesthetics utilizing MH precautions over a five-year period. The electronic medical record was further queried for patients diagnosed with MH. The indication for MH precautions and uses of susceptibility testing are assessed. Secondary outcomes included a diagnosis of bona fide MH.

Results: A total of 125 patients received 174 anesthetics with MH precautions at a mean age of 114 months (0-363 months). Otolaryngology was the procedural service most frequently involved in the care of the cohort (n = 45; 26%). A reported personal or family history of MH (n = 102; 59%) was the most common indication for precautions, followed by muscular dystrophy (n = 29; 17%). No MH events occurred in the cohort and further review of ICD-9 and -10 diagnosis codes found no MH diagnoses. No study subjects received muscle biopsy and contracture testing and only 5 (4%) underwent genetic testing for genomic variants known to cause MH susceptibility. A case example is given to highlight the implications of a reported MH history.

Conclusion: Otolaryngologists should maintain a familiarity with the precautions necessary to manage patients at risk for MH and MH-like reactions. Without an accessible test to rule out susceptibility, surgeons must rely on a careful history to appropriately utilize precautions. An inappropriate label of "MH-susceptible" may result in decreased access to care and treatment delays.

Keywords: CACNA1S; Caffeine halothane contracture test; Genetic testing; Malignant hyperthermia; Malignant hyperthermia susceptibility; RYR1.

MeSH terms

  • Caffeine
  • Child
  • Disease Susceptibility / complications
  • Disease Susceptibility / diagnosis
  • Halothane
  • Humans
  • Malignant Hyperthermia* / diagnosis
  • Malignant Hyperthermia* / etiology
  • Malignant Hyperthermia* / therapy
  • Retrospective Studies
  • Surgeons*

Substances

  • Caffeine
  • Halothane